International Symposium on Pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes

in Endocrine-Related Cancer
Authors:
Karel PacakK Pacak, Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, United States

Search for other papers by Karel Pacak in
Current site
Google Scholar
PubMed
Close
and
Roderick J. Clifton-BlighR Clifton-Bligh, Department of Endocrinology , Royal North Shore Hospital, St Leonards, Australia

Search for other papers by Roderick J. Clifton-Bligh in
Current site
Google Scholar
PubMed
Close
View More View Less

Correspondence: Karel Pacak, Email: karel@mail.nih.gov
Restricted access

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $0.01
USD  $0.01

USD  $1.00
USD  $1.00

USD  $1.00
USD  $1.00

Pheochromocytomas and paragangliomas (PPGLs) are defined as neuroendocrine tumors that produce catecholamines. Many recent advances in their management, localization, treatment, as well as surveillance have significantly improved outcomes for patients with PPGLs or carriers of pathogenic genetic variants linked to the development of these tumors. At present those advances mainly include: the molecular stratification of PPGLs into 7 clusters, the 2017 WHO revised definition of these tumors, the presence of specific clinical features pointing towards PPGL, the use of plasma metanephrines and 3-methoxytyramine with specific reference limits to assess the likelihood of having a PPGL (e.g. patients at high and low risk) including age-specific reference limits, nuclear medicine guidelines outlining cluster- and metastatic disease-specific functional (here mainly positron emission tomography and metaiodobenzylguanidine scintigraphy) imaging in the precise diagnostic localization of PPGLs, the guidelines for using radio- vs chemotherapy for patients with metastatic disease, and the international consensus on initial screening and follow-up of asymptomatic germline SDHx pathogenic variant carriers. Furthermore, new collaborative efforts particularly based on multi-institutional and worldwide initiatives are now considered key forces in improving our understanding and knowledge about these tumors and future successful treatments or even preventative interventions.

 

  • Collapse
  • Expand